- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
New evidence that may help solve one of the great puzzles of 21st- century medicine was published today in a special section of the Journal of Investigative Medicine. It features leading scientists in the field brought together by The American Federation for Medical Research and the American Physiological Society.
Is chronic disease triggered by an infection? New evidence comes from scientists at NASA, Mayo Clinic, and Nanobac Pharmaceuticals who pioneered investigations into infectious calcifying particles.
A condition known as calcification occurs in most diseases on the leading cause of death list and in illnesses such as kidney, gallbladder and prostate stones. Calcification is also linked to chronic inflammation in atherosclerosis and end-stage renal disease, but it is unclear how this occurs.
Half-a-dozen papers in the Journal resulted from a symposium that assembled, for the first time in medical history, experts from biology, medicine and geology to debate these possible causes of calcification: chemical crystallization; cell-mediated crystallization; and potentially infectious calcifying nanoparticles (CNPs) that generate calcification.
One conclusion by symposium organizers: Although infection is just one of three potential causes of calcification, it deserves focus as a chronic disease trigger, based on new evidence presented.
"Increasingly, micro-organisms are being identified as an unexpected cause of disease..." writes symposium co-organizer and Mayo Clinic scientist Dr. Virginia Miller.
The symposium considered works by Dr. Neva Ciftcioglu and Dr.Olavi Kajander, lead scientists with Nanobac Pharmaceuticals, as well as two other works by Mayo researchers, which provide evidence that calcifying nanoparticles might be infectious and spark calcification in disease.
Although Dr. Miller says the idea of infectious nanoparticles is still controversial, she concludes that, "Nanoparticles might serve as an inflammatory stimulus that initiates cell transdifferentiation, stimulate the formation of matrix vesicles, or simply form a nidus for subsequent inorganic calcium accumulation."
Participants in the symposium included scientists from such world-class institutions as UCLA and various institutes in Europe.
Scientists from Nanobac Pharmaceuticals are the leading investigators on the issue of infection as a possible cause of calcification, and have published the most papers on this topic.
Neva Ciftcioglu, Ph.D., director of science at Nanobac Pharmaceuticals, is one of the scientists who originally isolated nanoparticles from mammalian blood and, working at NASA's Johnson Space Center, presented concepts of nanoparticles as a nidi for biomineralization.
Neal X. Chen, Ph.D., assistant professor in the Department of Medicine at Indiana University, reviews mechanisms of cell transdifferentiation and crystallization in renal cells.
John C. Lieske, MD, associate professor of Medicine, Mayo Clinic College of Medicine, continued the theme of calcification of renal tissue, in particular Randalls plaques, by presenting evidence for self-replicating, self-calcifying nanoparticles in renal stones.
Linda L. Demer, MD, Ph.D., professor of medicine, Division of Cardiology, The David Geffen School of Medicine at UCLA, reviewed transdifferentiation of vascular smooth muscle cells to a bone-associated phenotype and the importance of RANKL and receptor in that process.
Howard H.T. Hsu, Ph.D., associate professor, Department of Pathology, University of Kansas Medical Center, reviewed data supporting the contribution of matrix vesicles to vascular calcification and presents a provocative theory of the stimuli involved in their formation.
Karim Benzerara, Ph.D., Institut de Mineralogis et de Physique des Milieux Condenses and Institut de Physique du Globe of Paris, France, demonstrates how the state-of-the-art scanning transmission X-ray microscopy and near-edge x-ray absorption fine structure (NEXAFS) can be used to define the biochemical characteristics of nanoparticles isolated from the environment and human tissue.
About Nanobac Pharmaceuticals
Nanobac Pharmaceuticals Inc. ((OTCBB:NNBP)) is dedicated to the discovery and development of products and services to improve human health through the detection and treatment of calcifying nanoparticles (CNPs). The company's pioneering research is establishing the pathogenic role of CNPs in soft tissue calcification, particularly in coronary artery, prostate and vascular disease. Nanobac's drug discovery and development is focused on new and existing compounds that effectively inhibit, destroy or neutralize CNPs. Nanobac manufactures In Vitro Diagnostic (IVD) kits and reagents for detecting calcifying nanoparticles. IVD products include a line of assays, proprietary antibodies, and reagents for uniquely recognizing CNPs. Nanobac's BioAnalytical Services works with biopharmaceutical partners to develop and apply methods for avoiding, detecting, and inactivating or eliminating CNPs from raw materials. For details visit http://www.nanobac.com.
Investors are cautioned that certain statements in this document, some statements in periodic press releases and some oral statements of Nanobac Pharmaceuticals, Inc. officials are "Forward-Looking Statements" within the meaning of the Private Securities Litigation Reform Act of 1995 (the "Act). Forward-Looking statements include statements which are predictive in nature, which depend upon or refer to future events or conditions, which include words such as "believes," "anticipates," "intends," "plans," "expects," and similar expressions. In addition, any statements concerning future financial performance (including future revenues, earnings or growth rates), ongoing business strategies or prospects, and possible future Nanobac Pharmaceuticals, Inc. actions, which may be provided by management, are also forward-looking statements as defined by the Act. Forward-Looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results, performance or achievements of the Company to materially differ from any future results, performance or achievements expressed or implied by such forward-looking statements and to vary significantly from reporting period to reporting period. Although management believes that the assumptions will, in fact, prove to be correct or that actual future results will not be different from the expectations expressed in this report. These statements are not guarantees of future performance and Nanobac Pharmaceuticals, Inc. has no specific intention to update these statements.
For more information, please click here
Carson Chandler 202-367-1625,
Matt Taylor, 202-367-1631
Copyright © Nanobac PharmaceuticalsIf you have a comment, please Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
|Related News Press|
The NanoWizardŽ AFM from JPK is applied for interdisciplinary research at the University of South Australia for applications including smart wound healing and how plants can protect themselves from toxins July 26th, 2016
Accurate design of large icosahedral protein nanocages pushes bioengineering boundaries: Scientists used computational methods to build ten large, two-component, co-assembling icosahedral protein complexes the size of small virus coats July 25th, 2016
Nanometrics Reports Second Quarter 2016 Financial Results July 26th, 2016
Ultrasensitive sensor using N-doped graphene July 26th, 2016
Call for NanoArt and Art-Science-Technology Papers June 9th, 2016
Are humans the new supercomputer?Today, people of all backgrounds can contribute to solving serious scientific problems by playing computer games. A Danish research group has extended the limits of quantum physics calculations and simultaneously blurred the boundaries between mac April 14th, 2016